2017 Tyrosine Kinase Inhibitor Abstracts


Risk of hypertension treated with aflibercept in recommended dose and dose-escalation studies: A systemic review and meta-analysis

Presenting Author: Miss. Bo Guan, Student, Dalian Medical University, Dalian, China



Cardiovascular and metabolic risk in patients with chronic myeloid leukemia in chronic phase receiving first-line BCR-ABL1 tyrosine kinase inhibitors in the United States

Presenting Author: Prof. Michael Mauro, Professor of Medicine; Clinical Director, Leukemia Services, Memorial Sloan Kettering Cancer Center, New York, NY, USA



Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Presenting Author: Dr. Daniel Pinkhas, Internal Medicine Resident, PGY-2, The Ohio State University Wexner Medical Centre, Columbus, OH, USA